https://www.biopharmawatch.com/news/ELUT/elutia-secures-funding-nxt-41x-launch BiopharmaWatch en 2026-08-13T20:10:00.000Z Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/CELC/celcuity-reports-q2-2026-results-and-corporate-update BiopharmaWatch en 2026-08-13T20:06:00.000Z Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/VANI/vivani-medical-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T20:05:00.000Z Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/FBIO/fortress-biotech-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:05:00.000Z Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/ETON/eton-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:05:00.000Z Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/EQ/equillium-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:05:00.000Z Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/FDMT/4dmt-q2-2026-financial-results-highlights-milestones BiopharmaWatch en 2026-08-13T20:05:00.000Z 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones https://www.biopharmawatch.com/news/ICCC/immucell-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:05:00.000Z ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 https://www.biopharmawatch.com/news/GLAS/glass-house-brands-q2-2026-results BiopharmaWatch en 2026-08-13T20:05:00.000Z Glass House Brands Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IVVD/invivyd-q2-2026-financial-results-business-highlights BiopharmaWatch en 2026-08-13T20:05:00.000Z Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T20:05:00.000Z Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KYNB/kyntra-bio-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-13T20:02:00.000Z Kyntra Bio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-q2-2026-financial-results-clinical-updates BiopharmaWatch en 2026-08-13T20:02:00.000Z Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates https://www.biopharmawatch.com/news/GOSS/gossamer-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T20:01:00.000Z Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CODX/co-diagnostics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:01:00.000Z Co-Diagnostics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-proposed-public-offering BiopharmaWatch en 2026-08-13T20:01:00.000Z Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering https://www.biopharmawatch.com/news/SPRY/ars-pharmaceuticals-strategic-priorities-q2-2026-results BiopharmaWatch en 2026-08-13T20:01:00.000Z ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALMS/alumis-reports-q2-2026-results-and-achievements BiopharmaWatch en 2026-08-13T20:01:00.000Z Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:01:00.000Z Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/AKTS/aktis-oncology-q2-2026-results BiopharmaWatch en 2026-08-13T20:01:00.000Z Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 https://www.biopharmawatch.com/news/HTFL/heartflow-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:01:00.000Z Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance https://www.biopharmawatch.com/news/KOD/kodiak-sciences-q2-2026-results-highlights BiopharmaWatch en 2026-08-13T20:00:00.000Z Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:00:00.000Z Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates https://www.biopharmawatch.com/news/MDXH/mdxhealth-q2-2026-financial-results BiopharmaWatch en 2026-08-13T20:00:00.000Z Mdxhealth Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q2-2026-results BiopharmaWatch en 2026-08-13T20:00:00.000Z ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights https://www.biopharmawatch.com/news/ZTS/zoetis-emergency-use-authorization-simparica-trio BiopharmaWatch en 2026-08-13T19:51:00.000Z Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies https://www.biopharmawatch.com/news/NTHI/neonc-patent-portfolio-nthi-potential BiopharmaWatch en 2026-08-13T18:31:00.000Z The Nose Knows: Why NeOnc’s Patent Portfolio Could Make NTHI More Than a One-Drug Biotech https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-q2-2026-results BiopharmaWatch en 2026-08-13T17:54:00.000Z Samenvatting: SBC Medical Group Holdings maakt financiële resultaten over tweede kwartaal van 2026 bekend https://www.biopharmawatch.com/news/SBC/sbc-medical-group-holdings-q2-2026-results BiopharmaWatch en 2026-08-13T17:54:00.000Z SBC Medical Group Holdings gibt die Finanzergebnisse für das zweite Quartal 2026 bekannt https://www.biopharmawatch.com/news/SEER/seer-inc-board-acquisition-offers BiopharmaWatch en 2026-08-13T17:00:00.000Z Radoff-JEC Group Calls on Seer, Inc.’s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-july-2026 BiopharmaWatch en 2026-08-13T16:34:00.000Z Sanofi: Information concerning the total number of voting rights and shares - July 2026 https://www.biopharmawatch.com/news/VALN/valneva-semi-annual-report-2026 BiopharmaWatch en 2026-08-13T15:45:00.000Z Rapport Semestriel 2026 Valneva https://www.biopharmawatch.com/news/VALN/valneva-half-year-2026-financial-report BiopharmaWatch en 2026-08-13T15:45:00.000Z Valneva Half-Year 2026 Financial Report https://www.biopharmawatch.com/news/NTRB/nutriband-ceo-gareth-sheridan-georgia-summit-2026 BiopharmaWatch en 2026-08-13T14:52:25.000Z Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-private-placement-offering BiopharmaWatch en 2026-08-13T14:00:00.000Z WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/NRSN/neurosense-ceo-letter-shareholders-update BiopharmaWatch en 2026-08-13T13:30:00.000Z NeuroSense Issues CEO Letter to Shareholders https://www.biopharmawatch.com/news/OPK/opko-health-expands-relationship-healthcare-royalty BiopharmaWatch en 2026-08-13T13:15:00.000Z OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests https://www.biopharmawatch.com/news/MPLT/maplight-therapeutics-150-million-financing BiopharmaWatch en 2026-08-13T13:10:00.000Z MapLight Therapeutics Announces $150 Million Private Placement Financing https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-private-placement-offering BiopharmaWatch en 2026-08-13T13:07:00.000Z bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/LEXX/lexaria-material-transfer-agreement-pegbio BiopharmaWatch en 2026-08-13T13:01:19.000Z Lexaria Enters a Material Transfer Agreement With PegBio https://www.biopharmawatch.com/news/MRK/sarah-cannon-merck-oncology-trials-access BiopharmaWatch en 2026-08-13T13:00:00.000Z Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials https://www.biopharmawatch.com/news/BFRI/biofrontera-q2-2026-financial-results BiopharmaWatch en 2026-08-13T12:51:00.000Z Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth https://www.biopharmawatch.com/news/OSTX/os-therapies-fda-meeting-ost-her2-survival-data BiopharmaWatch en 2026-08-13T12:45:00.000Z OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma https://www.biopharmawatch.com/news/CING/cingulate-q2-2026-results-ctxt-1301-update BiopharmaWatch en 2026-08-13T12:30:00.000Z Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-business-updates-q2-2026-results BiopharmaWatch en 2026-08-13T12:30:00.000Z Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/FATE/fate-therapeutics-q2-2026-results-updates BiopharmaWatch en 2026-08-13T12:30:00.000Z Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/PDSB/pds-biotech-reports-q2-2026-results BiopharmaWatch en 2026-08-13T12:30:00.000Z PDS Biotech Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/DWTX/dogwood-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-13T12:30:00.000Z Dogwood Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ASBP/aspire-biopharma-sidoti-conference-2026 BiopharmaWatch en 2026-08-13T12:15:00.000Z Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th https://www.biopharmawatch.com/news/PULM/pulmatrix-q2-2026-financial-results-merger-progress BiopharmaWatch en 2026-08-13T12:15:00.000Z Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger https://www.biopharmawatch.com/news/HCTI/healthcare-triangle-q2-2026-financial-results BiopharmaWatch en 2026-08-13T12:15:00.000Z Healthcare Triangle Reports 322% Increase in Gross Profit and 158% Increase in Revenue for Q2 2026 https://www.biopharmawatch.com/news/RIGL/rigel-launches-veppanu-fda-approval-breast-cancer BiopharmaWatch en 2026-08-13T12:05:00.000Z Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer https://www.biopharmawatch.com/news/CADL/candel-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-13T12:05:00.000Z Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/MGTX/meiragtx-reports-q2-2026-results BiopharmaWatch en 2026-08-13T12:00:57.000Z MeiraGTx Reports Second Quarter 2026 Financial and Operational Results https://www.biopharmawatch.com/news/DYAI/dyadic-international-secures-funding BiopharmaWatch en 2026-08-13T12:00:00.000Z Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-evercore-china-biotech-summit BiopharmaWatch en 2026-08-13T12:00:00.000Z Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit https://www.biopharmawatch.com/news/EPRX/eupraxia-phase-1b-2a-resolve-trial-results BiopharmaWatch en 2026-08-13T12:00:00.000Z Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients https://www.biopharmawatch.com/news/ARTL/artelo-biosciences-business-update-q2-2026-results BiopharmaWatch en 2026-08-13T12:00:00.000Z Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results https://www.biopharmawatch.com/news/CRIS/curis-announces-pricing-public-offering BiopharmaWatch en 2026-08-13T12:00:00.000Z Curis, Inc. Announces Pricing of $5.6 Million Public Offering https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-business-update-q2-2026-results BiopharmaWatch en 2026-08-13T12:00:00.000Z Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-q1-2027-financial-results BiopharmaWatch en 2026-08-13T12:00:00.000Z Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:30:00.000Z ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates https://www.biopharmawatch.com/news/ASND/ascendis-pharma-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:30:00.000Z Ascendis Pharma Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CRMD/cormedix-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:30:00.000Z Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/NGEN/nervgen-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:30:00.000Z NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ABEO/abeona-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-13T11:30:00.000Z Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/CABA/cabaletta-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T11:30:00.000Z Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/INKT/mink-therapeutics-phase-2-trial-results-2026 BiopharmaWatch en 2026-08-13T11:30:00.000Z MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:15:00.000Z Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/LIMN/liminatus-pharma-nasdaq-transfer-compliance-extension BiopharmaWatch en 2026-08-13T11:15:00.000Z Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement https://www.biopharmawatch.com/news/PTHS/pelthos-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:10:00.000Z Pelthos Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HLF/herbalife-midwest-ideas-investor-conference-2026 BiopharmaWatch en 2026-08-13T11:05:00.000Z Herbalife to Present and Host 1x1 Investor Meetings at Midwest IDEAS Investor Conference on August 26 https://www.biopharmawatch.com/news/YARW/yarrow-bioscience-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:00:00.000Z Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/AVAH/aveanna-healthcare-q2-2026-results-guidance BiopharmaWatch en 2026-08-13T11:00:00.000Z Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance https://www.biopharmawatch.com/news/OLMA/olema-oncology-appoints-jason-obyrne-cfo BiopharmaWatch en 2026-08-13T11:00:00.000Z Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer https://www.biopharmawatch.com/news/MDWD/medi-wound-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T11:00:00.000Z MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T11:00:00.000Z Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/PYXS/pyxis-oncology-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:00:00.000Z Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones https://www.biopharmawatch.com/news/LNSR/lensar-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-13T11:00:00.000Z LENSAR® Reports Second Quarter 2026 Results and Provides Business Update https://www.biopharmawatch.com/news/AMS/american-shared-hospital-services-q2-2026-results BiopharmaWatch en 2026-08-13T11:00:00.000Z American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results https://www.biopharmawatch.com/news/INDP/indaptus-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:00:00.000Z Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/XAIR/beyond-air-reports-financial-results-june-2026 BiopharmaWatch en 2026-08-13T11:00:00.000Z Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update https://www.biopharmawatch.com/news/PFSA/profusa-reverse-stock-split-2026 BiopharmaWatch en 2026-08-13T11:00:00.000Z Profusa Announces 1-for-4 Reverse Stock Split https://www.biopharmawatch.com/news/SGMT/sagimet-fda-phase-3-trial-denifanstat-acne BiopharmaWatch en 2026-08-13T11:00:00.000Z Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients https://www.biopharmawatch.com/news/BMEA/biomea-fusion-opal-study-icovamenib-semaglutide BiopharmaWatch en 2026-08-13T11:00:00.000Z Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-q2-2026-financial-results BiopharmaWatch en 2026-08-13T11:00:00.000Z Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/PRQR/proqr-announces-q2-2026-results BiopharmaWatch en 2026-08-13T11:00:00.000Z ProQR Announces Second Quarter 2026 Operating and Financial Results https://www.biopharmawatch.com/news/SBC/sbc-medical-group-q2-2026-results BiopharmaWatch en 2026-08-13T10:30:00.000Z SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECH/bio-techne-corrects-dividend-announcement BiopharmaWatch en 2026-08-13T10:30:00.000Z Bio-Techne Corrects Dividend Announcement https://www.biopharmawatch.com/news/RMTI/rockwell-medical-q2-2026-results BiopharmaWatch en 2026-08-13T10:00:00.000Z Rockwell Medical Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-q2-2026-results-symphony-il-6 BiopharmaWatch en 2026-08-13T10:00:00.000Z Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization https://www.biopharmawatch.com/news/PHAR/pharming-launches-joenja-japan-apds BiopharmaWatch en 2026-08-13T05:00:00.000Z Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older https://www.biopharmawatch.com/news/VALN/valneva-half-year-2026-financial-results BiopharmaWatch en 2026-08-13T05:00:00.000Z Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/BLTE/belite-bio-q2-2026-financial-results-update BiopharmaWatch en 2026-08-13T01:45:00.000Z Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-public-offering-lytenava BiopharmaWatch en 2026-08-13T01:45:00.000Z Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants https://www.biopharmawatch.com/news/CGEM/zipalertinib-phase-3-rezilient3-trial-results BiopharmaWatch en 2026-08-12T23:30:00.000Z Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/MDCX/medicus-pharma-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T22:06:51.000Z Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ARAY/accuray-strategic-leadership-appointments BiopharmaWatch en 2026-08-12T21:09:00.000Z Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments https://www.biopharmawatch.com/news/AZTR/azitra-announces-q2-2026-results-business-updates BiopharmaWatch en 2026-08-12T21:00:00.000Z Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates https://www.biopharmawatch.com/news/TTRX/turn-therapeutics-corporate-updates-q2-2026-results BiopharmaWatch en 2026-08-12T20:30:00.000Z Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BGMS/bio-green-med-solution-q2-financial-results-update BiopharmaWatch en 2026-08-12T20:15:00.000Z BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-q2-2026-update BiopharmaWatch en 2026-08-12T20:15:00.000Z First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/AEON/aeon-biopharma-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T20:15:00.000Z AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KLRA/kailera-q2-2026-financial-results-business-updates BiopharmaWatch en 2026-08-12T20:05:51.000Z Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/ACRV/acrivon-q2-2026-financial-results-clinical-data-catalysts BiopharmaWatch en 2026-08-12T20:05:37.000Z Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts https://www.biopharmawatch.com/news/ATRA/atara-biotherapeutics-q2-2026-results BiopharmaWatch en 2026-08-12T20:05:00.000Z Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress https://www.biopharmawatch.com/news/QTI/qt-imaging-second-quarter-growth-commercial-scale BiopharmaWatch en 2026-08-12T20:05:00.000Z QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale https://www.biopharmawatch.com/news/TLPH/talphera-announces-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update https://www.biopharmawatch.com/news/SERA/sera-prognostics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:05:00.000Z SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/BSEM/biostem-technologies-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:05:00.000Z BioStem Technologies Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/BCDA/biocardia-reports-q2-2026-results-and-highlights BiopharmaWatch en 2026-08-12T20:05:00.000Z BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results https://www.biopharmawatch.com/news/RNXT/renovorx-reports-record-q2-2026-results BiopharmaWatch en 2026-08-12T20:05:00.000Z RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth https://www.biopharmawatch.com/news/LMRI/lumexa-imaging-q2-2026-results BiopharmaWatch en 2026-08-12T20:05:00.000Z Lumexa Imaging Announces Second Quarter 2026 Results https://www.biopharmawatch.com/news/MXCT/maxcyte-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:05:00.000Z MaxCyte Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALGS/aligos-therapeutics-phase-1-study-alg-170675 BiopharmaWatch en 2026-08-12T20:05:00.000Z Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q2-2026-results-business-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CNTB/connect-biopharma-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ICU/seastar-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:05:00.000Z SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/LGVN/longeveron-announces-2026-q2-financial-results-business-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ALLO/allogene-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T20:05:00.000Z Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/RPRX/zealand-pharma-royalty-agreement-rusfertide BiopharmaWatch en 2026-08-12T20:05:00.000Z Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:03:00.000Z Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/OMER/omeros-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:02:00.000Z Omeros Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/KURA/kura-oncology-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:02:00.000Z Kura Oncology Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-12T20:01:00.000Z Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update https://www.biopharmawatch.com/news/PTCT/ptc-expand-rare-disease-portfolio-acquisition-st-920 BiopharmaWatch en 2026-08-12T20:01:00.000Z PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program https://www.biopharmawatch.com/news/OTLK/outlook-therapeutics-public-offering BiopharmaWatch en 2026-08-12T20:01:00.000Z Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants https://www.biopharmawatch.com/news/DERM/journey-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:01:00.000Z Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/DERM/journey-medical-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:01:00.000Z Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights https://www.biopharmawatch.com/news/HYPD/hyperion-defi-q2-2026-financial-results BiopharmaWatch en 2026-08-12T20:01:00.000Z Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum https://www.biopharmawatch.com/news/AVBP/arrivent-biopharma-second-quarter-2026-results BiopharmaWatch en 2026-08-12T20:01:00.000Z ArriVent BioPharma Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/STAA/staaar-surgical-reports-q2-2026-results BiopharmaWatch en 2026-08-12T20:01:00.000Z STAAR Surgical Reports Second Quarter 2026 Results https://www.biopharmawatch.com/news/NTHI/neoncs-ne100-phase-2a-results-brain-cancer BiopharmaWatch en 2026-08-12T13:38:00.000Z Targeting The Mutant: NTHI’s NEO100 Data Could Open a New Front in the Fight Against Brain Cancer https://www.biopharmawatch.com/news/GMAB/genmab-publishes-articles-of-association BiopharmaWatch en 2026-08-12T13:32:36.000Z Genmab A/S has published its Articles of Association https://www.biopharmawatch.com/news/MNPR/monopar-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T13:30:00.000Z Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-approval-china-squamous-nsclc BiopharmaWatch en 2026-08-12T13:22:00.000Z Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/FRNM/freenome-fda-breakthrough-device-simple-screen-lung-cancer BiopharmaWatch en 2026-08-12T13:00:00.000Z FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test https://www.biopharmawatch.com/news/FEMY/femasys-global-patent-protection-fembloc BiopharmaWatch en 2026-08-12T13:00:00.000Z Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-08-12T13:00:00.000Z Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/CVS/cvs-caremark-employers-pharmacy-benefit-manager BiopharmaWatch en 2026-08-12T13:00:00.000Z New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions https://www.biopharmawatch.com/news/AIM/aim-immunotech-biodefense-military-force-protection BiopharmaWatch en 2026-08-12T12:44:00.000Z AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article https://www.biopharmawatch.com/news/FEED/envue-medical-secures-equity-financing-facility BiopharmaWatch en 2026-08-12T12:35:00.000Z ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-midwest-ideas-investor-conference BiopharmaWatch en 2026-08-12T12:32:00.000Z Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:30:00.000Z Aprea Therapeutics Announces Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-prp-therapy-ras-driven-cancers BiopharmaWatch en 2026-08-12T12:30:00.000Z Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers https://www.biopharmawatch.com/news/NBIX/ingrezza-kinect-pro-findings-quality-of-life BiopharmaWatch en 2026-08-12T12:30:00.000Z Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia https://www.biopharmawatch.com/news/SPRC/neurothera-japanese-patent-innovative-therapy BiopharmaWatch en 2026-08-12T12:25:00.000Z SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination https://www.biopharmawatch.com/news/VNRX/volition-rapid-point-of-care-sepsis-test BiopharmaWatch en 2026-08-12T12:17:00.000Z Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients https://www.biopharmawatch.com/news/AMIX/autonomix-medical-glp-preclinical-study-fda-submission BiopharmaWatch en 2026-08-12T12:15:00.000Z Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission https://www.biopharmawatch.com/news/SCNX/scienture-launches-rezenopy-naloxone-nasal-spray BiopharmaWatch en 2026-08-12T12:05:00.000Z SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray https://www.biopharmawatch.com/news/CNSP/cns-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-12T12:04:17.000Z CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation https://www.biopharmawatch.com/news/ACXP/acurx-pharmaceuticals-new-patents-dna-polymerase-inhibitors BiopharmaWatch en 2026-08-12T12:01:00.000Z Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics https://www.biopharmawatch.com/news/NTHI/neonc-technologies-phase-2a-results-neoi00 BiopharmaWatch en 2026-08-12T12:00:59.000Z NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma https://www.biopharmawatch.com/news/HSDT/solana-company-release-q2-2026-results BiopharmaWatch en 2026-08-12T12:00:51.000Z Solana Company to Release Second Quarter 2026 Operating Results on August 14, 2026 https://www.biopharmawatch.com/news/IPSC/century-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:00:44.000Z Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates https://www.biopharmawatch.com/news/AVLN/avalyn-reports-q2-2026-financial-results BiopharmaWatch en 2026-08-12T12:00:43.000Z Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/BBLG/bone-biologics-32-month-shelf-life-rhnell-1 BiopharmaWatch en 2026-08-12T12:00:00.000Z Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1 https://www.biopharmawatch.com/news/MDGL/madrigal-appoints-john-reed-board-directors BiopharmaWatch en 2026-08-12T12:00:00.000Z Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors https://www.biopharmawatch.com/news/TVRD/tvardi-webinar-tti-109-ulcerative-colitis BiopharmaWatch en 2026-08-12T12:00:00.000Z Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 https://www.biopharmawatch.com/news/SPRB/cure-sanfilippo-foundation-investment-spruce-biosciences BiopharmaWatch en 2026-08-12T12:00:00.000Z Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences https://www.biopharmawatch.com/news/CTOR/citius-oncology-appoints-independent-director-jonathan-peri BiopharmaWatch en 2026-08-12T12:00:00.000Z Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-08-12T11:30:18.000Z Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates https://www.biopharmawatch.com/news/ADAG/adagene-financial-results-corporate-updates-2026 BiopharmaWatch en 2026-08-12T11:30:00.000Z Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/PYPD/polypid-corporate-update-q2-2026-results BiopharmaWatch en 2026-08-12T11:30:00.000Z PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALT/altimmune-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T11:30:00.000Z Altimmune Announces Second Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-q2-2026-financial-results-update BiopharmaWatch en 2026-08-12T11:19:00.000Z Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q2-2026-results-update BiopharmaWatch en 2026-08-12T11:08:00.000Z Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KMDA/kamada-record-high-financial-results-2026 BiopharmaWatch en 2026-08-12T11:05:00.000Z Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-us-patent-ath434 BiopharmaWatch en 2026-08-12T11:05:00.000Z Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434 https://www.biopharmawatch.com/news/LONA/leonabio-highlight-lasofoxifene-breast-cancer-summit BiopharmaWatch en 2026-08-12T11:00:18.000Z LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer https://www.biopharmawatch.com/news/LXEO/lexeo-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-12T11:00:10.000Z Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q2-2026-results-highlights BiopharmaWatch en 2026-08-12T11:00:10.000Z Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/TCRX/tscan-therapeutics-q2-2026-results-update BiopharmaWatch en 2026-08-12T11:00:08.000Z TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/KMDA/kamada-cfo-transition-chaime-orlev BiopharmaWatch en 2026-08-12T11:00:00.000Z Kamada Announces Planned Transition of Chief Financial Officer https://www.biopharmawatch.com/news/STRO/sutro-biopharma-stro-004-phase-1-update BiopharmaWatch en 2026-08-12T11:00:00.000Z Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study https://www.biopharmawatch.com/news/HUMA/humacyte-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-12T11:00:00.000Z Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CANF/can-fite-fda-ema-regulatory-status-phase-iii-drugs BiopharmaWatch en 2026-08-12T11:00:00.000Z Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-phase-3-voyage-study-results BiopharmaWatch en 2026-08-12T11:00:00.000Z Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder https://www.biopharmawatch.com/news/UNH/unitedhealth-group-quarterly-dividend-2026 BiopharmaWatch en 2026-08-12T11:00:00.000Z UnitedHealth Group Board Authorizes Payment of Quarterly Dividend https://www.biopharmawatch.com/news/PHVS/pharvaris-q2-2026-financial-results-business-update BiopharmaWatch en 2026-08-12T10:50:07.000Z Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-q2-2026-results BiopharmaWatch en 2026-08-12T10:50:00.000Z Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results https://www.biopharmawatch.com/news/BDX/bdx-prevent-trial-phasix-mesh-hernia-prevention BiopharmaWatch en 2026-08-12T10:50:00.000Z BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-q2-2026-financial-results BiopharmaWatch en 2026-08-12T10:30:00.000Z Liquidia Corporation Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TECH/bio-techne-fourth-quarter-fiscal-2026-results BiopharmaWatch en 2026-08-12T10:30:00.000Z Bio-Techne Releases Fourth Quarter Fiscal 2026 Results https://www.biopharmawatch.com/news/ANNX/annexon-reports-q2-2026-results-business-updates BiopharmaWatch en 2026-08-12T10:05:28.000Z Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones https://www.biopharmawatch.com/news/ANNX/annexon-expands-vonaprument-phase-3-program-geographic-atrophy BiopharmaWatch en 2026-08-12T10:00:32.000Z Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study https://www.biopharmawatch.com/news/NTRA/natera-support-clinical-trial-ctdna-advanced-skin-cancers BiopharmaWatch en 2026-08-12T10:00:00.000Z Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers https://www.biopharmawatch.com/news/EYE/national-vision-holdings-q2-2026-results BiopharmaWatch en 2026-08-12T10:00:00.000Z National Vision Holdings, Inc. Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ELOX/elox-reports-q2-2026-results-business-update BiopharmaWatch en 2026-08-12T10:00:00.000Z Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/LLY/lilly-fights-retatrutide-black-market BiopharmaWatch en 2026-08-12T09:30:00.000Z Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market https://www.biopharmawatch.com/news/SLBT/new-framework-developing-gamma-d-t-cell-therapy-glioblastoma BiopharmaWatch en 2026-08-12T03:49:34.000Z A New Framework for Developing γδ T Cell Therapy in Glioblastoma https://www.biopharmawatch.com/news/SLBT/t-cell-therapy-glioblastoma-framework BiopharmaWatch en 2026-08-12T03:49:19.000Z 現成型細胞治療的新可能——γδ T細胞對抗膠質母細胞瘤 https://www.biopharmawatch.com/news/SLN/silence-therapeutics-upsized-public-offering BiopharmaWatch en 2026-08-12T03:20:00.000Z Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering https://www.biopharmawatch.com/news/ALGN/align-technology-patent-victory-china BiopharmaWatch en 2026-08-12T00:47:00.000Z Align Technology Prevails in China Patent Infringement Action Against Angelalign https://www.biopharmawatch.com/news/SLXN/silexion-therapeutics-pricing-public-offering BiopharmaWatch en 2026-08-12T00:01:00.000Z Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering https://www.biopharmawatch.com/news/CYPH/leap-therapeutics-defiance-study-results-sirexatamab BiopharmaWatch en 2026-08-12T00:00:00.000Z Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from ... https://www.biopharmawatch.com/news/CYPH/cypherpunk-technologies-q2-2026-financial-results BiopharmaWatch en 2026-08-12T00:00:00.000Z Cypherpunk Technologies Reports Second Quarter 2026 Financial Results Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the second quarter ended June 30, 2026. "In the... https://www.biopharmawatch.com/news/EPRX/eupraxia-pharmaceuticals-q2-2026-results BiopharmaWatch en 2026-08-11T21:22:14.000Z Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AARD/aardvark-therapeutics-q2-2026-results BiopharmaWatch en 2026-08-11T20:54:17.000Z Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates https://www.biopharmawatch.com/news/APLM/apollomics-announces-10-million-private-placement BiopharmaWatch en 2026-08-11T20:36:18.000Z Apollomics Announces $10 Million Private Placement Transaction